Little Fly labs

Imagine controlling vector-borne disease without the use of pesticides, vaccines or the eradication of an essential species.

The threat of vector-borne disease continues to increase as climate change and jet travel expand the mosquito’s geographic footprint, pathogens are continually mutating and traveling fast.



80% of the world is at risk from vector-borne diseases

Vector-borne diseases account for more than 17% of all infectious diseases, and kill over 700,000 people per year

More than 3.9 billion people in over 128 countries are at risk of contracting dengue, with 96 million cases estimated per year

Little Fly Labs is developing innovative solutions to control mosquito-borne diseases such as Zika, dengue, chikungunya, yellow fever and West Nile virus. Our Transbiotics gene-silencing technology utilizes enteric bacteria to deliver species-specific and gene-specific double-stranded RNA to selectively inactivate the disease-causing viruses in each mosquito, without affecting the environment or eradicating the species.

“Zika and other diseases spread by Aedes aegypti are really not controllable with current technologies.”

— Dr. Tom Frieden, former director of the Centers for Disease Control and Prevention

“Our objective is to eliminate the viruses from mosquitoes that cause so much human suffering and loss of life.”

— Dr. Richard Sayre, Chief Technology Officer at Little Fly Labs, October 2016

US $8+ billion is spent each year to combat vector-borne disease.